insights_auto
Proč je BT3 níž 3,35%?
Prozkoumat hloubějichevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
0,78 €
arrow_downward
-3,35%(-0,027) 1D
17. 11., 8:00:12 GMT+1 · EUR
search
Všechny symboly
| Symbol | Cena | Změna | Změna (%) |
|---|
insights_autoGenerování hlavních statistik pro BT3…
Otevřít
0,78 €
Max.
0,78 €
Min.
0,78 €
Trž. kap.
202,14 mil.
Prům. obj.
137,00
Objem
0,00
52týd. max.
1,68 €
52týd. min.
0,78 €
Počet zaměstnanců
75
Otevřít
0,78 €
Max.
0,78 €
Min.
0,78 €
Trž. kap.
202,14 mil.
Prům. obj.
137,00
Objem
0,00
52týd. max.
1,68 €
52týd. min.
0,78 €
Počet zaměstnanců
75
Zpravodajské články
Z webových zdrojů a od partnerů z oblasti zpravodajství
TradingView
·
před 2 hodinami
Stock Market: Will S&P 500 Open Up or Down Today?
ChartMill
·
před 13 hodinami
Today's Most-Active S&P 500 Stocks: Ford Leads Volume as SMCI and Micron Fall
The Motley Fool
·
před 13 hodinami
McDonald's Is Underperforming the S&P 500 and Nasdaq-100. Could January Mark a Turning Point?
Traders Union
·
před 9 hodinami
Michael A. Gayed: S&P 500 fell 19.35% and high yield dropped 5.9% in Q4 2018 selloff
Profil
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Informace o Lineage Cell Therapeutics Inc